The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Osteocytes are the most abundant (~95%) cells in bone with the longest half-life (~25 years) in humans. In the past osteocytes have been regarded as vestigial cells in bone, since they are buried inside the tough bone matrix. However, during the last 30 years it has become clear that osteocytes are as important as bone forming osteoblasts and bone resorbing osteoclasts in maintaining bone homeostasis. The osteocyte cell body and dendritic processes reside in bone in a complex lacuno-canalicular system, which allows the direct networking of osteocytes to their neighboring osteocytes, osteoblasts, osteoclasts, bone marrow, blood vessels, and nerves. Mechanosensing of osteocytes translates the applied mechanical force on bone to cellular signaling and regulation of bone adaptation. The osteocyte lacuno-canalicular system is highly efficient in transferring external mechanical force on bone to the osteocyte cell body and dendritic processes via displacement of fluid in the lacuno-canalicular space. Osteocyte mechanotransduction regulates the formation and function of the osteoblasts and osteoclasts to maintain bone homeostasis. Osteocytes produce a variety of proteins and signaling molecules such as sclerostin, cathepsin K, Wnts, DKK1, DMP1, IGF1, and RANKL/OPG to regulate osteoblast and osteoclast activity. Various genetic abnormality-associated rare bone diseases are related to disrupted osteocyte functions, including sclerosteosis, van Buchem disease, hypophosphatemic rickets, and WNT1 and plastin3 mutation-related disorders. Meticulous studies during the last 15 years on disrupted osteocyte function in rare bone diseases guided for the development of various novel therapeutic agents to treat bone diseases. Studies on genetic, molecular, and cellular mechanisms of sclerosteosis and van Buchem disease revealed a role for sclerostin in bone homeostasis, which led to the development of the sclerostin antibody to treat osteoporosis and other bone degenerative diseases. The mechanism of many other rare bone diseases and the role of the osteocyte in the development of such conditions still needs to be investigated. In this review, we mainly discuss the knowledge obtained during the last 30 years on the role of the osteocyte in rare bone diseases. We speculate about future research directions to develop novel therapeutic drugs targeting osteocyte functions to treat both common and rare bone diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
The biogenesis, biology and characterization of circular RNAs
Kristensen, L. S., Andersen, M. S., Stagsted, L. V. W., Ebbesen, K. K., Hansen, T. B., & Kjems, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0158-7 · Cited by 4,823
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093 · cited 2×
“On the other hand, Wnt inhibition causes overexpression of RANKL and deregulation of OPG resulting in osteoclastogenesis (38).”
BackgroundEvidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Feng, J. Q., Ward, L. M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S. I., Zhang, S., et al. (2006) · Nature Genetics · doi:10.1038/ng1905 · Cited by 1,199 · cited 2×
“One autosomal recessive hypophosphatemic rickets family carried a mutation affecting the dentin matrix protein (DMP1) start codon (112).”
BackgroundIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 5×
“Sclerostin deficiency in various rare genetic bone diseases, such as sclerosteosis and van Buchem disease, causes osteopetrosis, a high bone mass phenotype (36).”
BackgroundInfluentialThe Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 2×
“In the case of sclerostin deficiency, osteocytes become like a “snake without fang” and are unable to control new bone deposition by osteoblasts (36, 37).”
BackgroundIrisin Mediates Effects on Bone and Fat via αV Integrin Receptors
Kim, H., Wrann, C. D., Jedrychowski, M., Vidoni, S., Kitase, Y., Nagano, K., Zhou, C., Chou, J., Parkman, V.-J. A., Novick, S. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.025 · Cited by 638
Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599
Mechanosensation and transduction in osteocytes
Klein-Nulend, J., Bakker, A. D., Bacabac, R. G., Vatsa, A., & Weinbaum, S. (2013) · Bone · doi:10.1016/j.bone.2012.10.013 · Cited by 528
Self-citationSclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503 · cited 1×
“Studies on the role of osteocytic RANKL in bone homeostasis have led to the development of an anti-RANKL monoclonal antibody to treat common metabolic bone diseases, including osteoporosis (196, 197).”
BackgroundTherapeutic management of hypophosphatemic rickets from infancy to adulthood
Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331 · cited 1×
“A combination of oral phosphorous supplementation and active vitamin D analogs is the conventional therapy to counteract the consequences of excessive FGF23 in hypophosphatemic rickets (113).”
BackgroundXiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusevich, V., Bonewald, L., Manolagas, S. C., & O’Brien, C. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138189 · Cited by 323
PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling
Rhee, Y., Allen, M. R., Condon, K., Lezcano, V., Ronda, A. C., Galli, C., Olivos, N., Passeri, G., O'Brien, C. A., Bivi, N., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.304 · Cited by 208
Morrell, A. E., Brown, G. N., Robinson, S. T., Sattler, R. L., Baik, A. D., Zhen, G., Cao, X., Bonewald, L. F., Jin, W., Kam, L. C., et al. (2018) · Bone Research · doi:10.1038/s41413-018-0007-x · Cited by 184
Degeneration of the osteocyte network in the C57BL/6 mouse model of aging
Tiede-Lewis, L. M., Xie, Y., Hulbert, M. A., Campos, R., Dallas, M. R., Dusevich, V., Bonewald, L. F., & Dallas, S. L. (2017) · Aging · doi:10.18632/aging.101308 · Cited by 176 · cited 1×
“Aging also reduces the number of osteocyte dendrites and canaliculi by ∼30% (80, 84).”
BackgroundSaini, V., Marengi, D. A., Barry, K. J., Fulzele, K. S., Heiden, E., Liu, X., Dedic, C., Maeda, A., Lotinun, S., Baron, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.441360 · Cited by 167
David, V., Martin, A., Hedge, A.-M., & Rowe, P. S. N. (2009) · Endocrinology · doi:10.1210/en.2009-0216 · Cited by 106
Dussold, C., Gerber, C., White, S., Wang, X., Qi, L., Francis, C., Capella, M., Courbon, G., Wang, J., Li, C., et al. (2019) · Bone Research · doi:10.1038/s41413-019-0051-1 · Cited by 96
Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity
William Lau, K.-H., Baylink, D. J., Zhou, X.-D., Rodriguez, D., Bonewald, L. F., Li, Z., Ruffoni, D., Müller, R., Kesavan, C., & Sheng, M. H.-C. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00092.2013 · Cited by 94
PTH signaling mediates perilacunar remodeling during exercise
Gardinier, J. D., Al-Omaishi, S., Morris, M. D., & Kohn, D. H. (2016) · Matrix Biology · doi:10.1016/j.matbio.2016.02.010 · Cited by 69
The Osteocyte Transcriptome Is Extensively Dysregulated in Mouse Models of Osteogenesis Imperfecta
Zimmerman, S. M., Dimori, M., Heard‐Lipsmeyer, M. E., & Morello, R. (2019) · JBMR Plus · doi:10.1002/jbm4.10171 · Cited by 41 · cited 1×
“The osteocyte transcriptome is extensively deregulated in a mouse model of osteogenesis imperfecta (163).”
Background
Cited by
The osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
The Development of Molecular Biology of Osteoporosis
Gao, Y., Patil, S., & Jia, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158182 · Cited by 116
The intricate mechanism of PLS3 in bone homeostasis and disease
Zhong, W., Pathak, J. L., Liang, Y., Zhytnik, L., Pals, G., Eekhoff, E. M. W., Bravenboer, N., & Micha, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168306 · Cited by 13
Self-citationHu, J., Zhou, B., Lin, X., Zhang, Q., Guan, F., Sun, L., Liu, J., Wang, O., Jiang, Y., Xia, W.-B., et al. (2023) · eLife · doi:10.7554/elife.80365 · Cited by 6
Metadata
- Authors
- Pathak, J. L., Bravenboer, N., & Klein-Nulend, J.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-08
- Volume
- 11
- Pages
- 405-405
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3041189104
- Cited by
- 53
- References
- 28
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.